Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 2 Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Sarcoma, Ewing 1 Prostatic Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Ovarian Carcinosarcoma 1 Osteosarcoma 1 Neuroblastoma 1 Leiomyosarcoma 1 Hemangiosarcoma 1

Interventions

Doxorubicin 25 Gemcitabine 16 Trabectedin 12 Ifosfamide 12 Radiotherapy 11 Docetaxel 10 Dacarbazine 8 pazopanib 7 Nivolumab 6 Specimen Handling 5 Biopsy 5 liposomal doxorubicin 4 Temozolomide 4 pembrolizumab 3 Sunitinib 3 Sorafenib 3 Radiation 3 Magnetic Resonance Spectroscopy 3 Filgrastim 3 rucaparib 2 pegfilgrastim 2 olaratumab 2 eribulin 2 durvalumab 2 cixutumumab 2 cemiplimab 2 brostallicin 2 belinostat 2 avelumab 2 X-Rays 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Leiomyosarcoma × niraparib × Sarcoma × Clear all

NCT05174455 2023-09-18

Niraparib for the Treatment of Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡